Immatics (IMTX) Earnings Date & Reports

A.I. Advisor

published Earnings

IMTX is expected to report earnings to rise 65.88% to -28 cents per share on November 12

Q3'24

Est.

$-0.28

Q2'24

Beat

by $0.11

Q1'24

Beat

by $0.16

Q4'23

Beat

by $0.01

Q3'23

Beat

by $0.04

The last earnings report on August 13 showed earnings per share of -17 cents, beating the estimate of -28 cents. With 71.40K shares outstanding, the current market capitalization sits at 1.21B.

View a ticker or compare two or three

Compare

IMTX

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if shorted

View Trends For IMTX
(Try 14 days for $1 only)

Ad is loading...

A.I.Advisor

published price charts

View to see Real Time Patterns for IMTX (Try 14 days for $1 only)

A.I. Advisor

published General Information

General Information

a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

Paul-Ehrlich-Strasse 15

Phone

+49 707153970

Employees

343

Web

https://www.immatics.com